Abbott Laboratories· ABT

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.

• 

  Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?

  The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

  Sep 16, 2026
• 

  Is AbbVie the Best Dividend King to Buy in September?

  It is certainly a good Dividend King to buy in September.

  Sep 16, 2026
• 

  Bank of America Corp DE Acquires Shares of 17,672,543 Abbott Laboratories $ABT

  Bank of America Corp DE purchased a new stake in Abbott Laboratories (NYSE: ABT) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 17,672,543 shares of the healthcare product maker's stock, valued at approximately $1,603,607,000. Bank of America Corp DE owned

  Sep 15, 2026
• 

  Billionaire Ken Griffin Just Loaded Up on This Dividend King, and Wall Street Still Sees Upside

  Citadel, Ken Griffin's hedge fund, materially increased its stake in AbbVie; here's why you may want to follow that lead.

  Sep 14, 2026
• 

  Abbott (ABT) Rises As Market Takes a Dip: Key Facts

  Abbott (ABT) closed the most recent trading day at $103.09, moving +1.12% from the previous trading session.

  Sep 14, 2026

• UB

  Abbott price target lowered to $125 from $135 at UBS

  UBS· Patrick Wood· $125.00
  Jul 28, 2026
• EI

  Abbott price target lowered to $112 from $120 at Evercore ISI

  Evercore ISI· Vijay Kumar· $112.00
  Jul 6, 2026
• RW

  Abbott initiated with an Outperform at Baird

  Robert W. Baird· David Rescott· $121.00
  Jun 30, 2026
• BA

  Abbott price target lowered to $143 from $144 at Barclays

  Barclays· Matt Miksic· $143.00
  Apr 20, 2026
• UB

  UBS Reiterates Buy Rating on Abbott Labs (ABT) on DD Medical Device Growth Sustainability

  UBS· Danielle Antalffy· $158.00
  Mar 13, 2026